biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Tomorrow...Tomorrow...Prothena's options expire tomorrow

<< Previous

Bullboard Posts

Next >>

Comment by chrispion Dec 30, 2020 8:36pm

171 Views

Post# 32200790

RE:RE:RE:RE:RE:RE:Tomorrow...Tomorrow...Prothena's options expire tomorrow

Maybe the question, pof, is whether Prothena has a payload worth transporting. The cost of xB3 to them is almost zero but the value could be huge if they have payload drugs that actually work and are worth putting tens, even hundreds of millions into preclinical and clinical programs to prove them.

I think that's the question I'd be asking.

Correct.
We don't control the drug pipeline of nor timeline for Prothena. If they exercise the option, great but if they don't, that's fine too. Perhaps they are behind in their studies for whatever reason(s) ... non-Bioasis related reasons.

We have many other more important initiatives and opportunitie$ with other partners that we are working on in the meantime.

<< Previous

Bullboard Posts

Next >>

AI companies to invest in